BioFlash-logo

BioFlash

Business News

BioFlash is a biweekly podcast, hosted by San Francisco Business Times biotech reporter Ron Leuty. From cancer immunotherapy to drug pricing, we explore the hot topics driving the life sciences ecosystem in the San Francisco Bay Area and beyond.

BioFlash is a biweekly podcast, hosted by San Francisco Business Times biotech reporter Ron Leuty. From cancer immunotherapy to drug pricing, we explore the hot topics driving the life sciences ecosystem in the San Francisco Bay Area and beyond.

Location:

United States

Description:

BioFlash is a biweekly podcast, hosted by San Francisco Business Times biotech reporter Ron Leuty. From cancer immunotherapy to drug pricing, we explore the hot topics driving the life sciences ecosystem in the San Francisco Bay Area and beyond.

Language:

English


Episodes

Where does drug pricing cross the line into gouging?

1/15/2018
Big money was evident throughout the 36th J.P. Morgan Healthcare Conference — from the $200 an hour it costs to meet with someone in some hotel lobbies or lounges to the price of drugs. But as life-changing, one-shot-and-you're-done gene therapies emerge as options — with price tags approaching or exceeding $1 million — how much is too much?

Duration:00:14:54

The iPhone, blockchain and other health themes from Stanford Medicine Dean Lloyd Minor

1/12/2018
Lloyd Minor, dean of the Stanford University School of Medicine, talks about the trends capturing health care and biotech. Lloyd Minor's list of three challenges that will define health care's future: https://www.linkedin.com/pulse/jpm-2018-three-challenges-define-health-cares-future-lloyd-minor/

Duration:00:28:11

From full-body scanners to new-age drugs, Mir Imran's passion for 'big, unsolved mysteries'

1/9/2018
Mir Imran developed an early defibrillator and those full-body scanners at airport security. After a career that's also included patents for medical devices, his Rani Therapeutics now is taking on new-age drugs designed to reduce side effects and increase efficacy.

Duration:00:39:05

How a venture fund weighs risk and spots scientific passion

1/8/2018
Nick Naclerio oversaw many deals by life sciences tools maker Illumina Inc. Now he's heading up a $230 million fund, which takes its name from and includes Illumina as an investor.

Duration:00:23:58

How a startup is using machine learning to speed new Parkinson's, ALS drugs

1/4/2018
Alice Zhang sees a way of tapping machine learning to accelerate the development of new drugs to treat Parkinson's disease and other brain diseases — and dismiss the ones that won't work.

Duration:00:22:42

What an emerging drug company is doing to disrupt depression

1/2/2018
Dr. Atul Mahableshwarkar, hired last summer by BlackThorn Therapeutics as vice president of clinical development, talks about the South San Francisco drug company's attack on depression.

Duration:00:28:40

How Glenn Close, Billy Crystal and a S.F. nonprofit are conquering the 'last frontier'

10/20/2017
Billy Crystal talks about the award he accepted from Bring Change To Mind, the mental health nonprofit cofounded by Glenn Close, while Close talks about eliminating the stigma of mental disorders and changing how mental health issues are discussed, diagnosed and treated.

Duration:00:11:42